Increased AP-1 activity in drug resistant human breast cancer MCF-7 cells

被引:100
作者
Daschner, PJ
Ciolino, HP
Plouzek, CA
Yeh, GC
机构
[1] NCI, Cellular Def & Carcinogenesis Sect, Basic Res Lab, FCRDC,NIH, Frederick, MD 21702 USA
[2] NCI, Intramural Res Support Program, SAIC, FCRDC, Frederick, MD 21702 USA
关键词
AP-1; MDR1; MCF-7; cells; multidrug resistance;
D O I
10.1023/A:1006138803392
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The expression, DNA binding, and transactivating activity of activator protein 1 (AP-1) was examined in a series of multidrug resistant (MDR) MCF-7 human breast cancer cells that have increasing levels of MDR1 gene expression. We observed an increase in the amount of both c-jun and c-fos mRNA in cells with 12-, 65-, or 200-fold higher resistance to adriamycin when compared to drug-sensitive MCF-7 wild type (WT) cells. Electrophoretic mobility shift assays (EMSA) demonstrated an increase in the DNA binding activity of an AP-1 complex in nuclear extracts from MDR MCF-7 cells when compared to extracts from WT cells. We observed a proportional increase in luciferase expression from a reporter vector containing consensus AP-1 binding sites in transiently transfected MDR cells when compared to WT cells, indicating that AP-1 mediated gene expression is increased in drug-resistant MCF-7 cells. Since the MDR1 promoter contains a putative AP-1 binding site, we used EMSA to examine AP-1 binding activity to an oligonucleotide probe that contained the relevant MDR1 promoter sequences (-123 to -108). Nuclear extracts from resistant MCF-7 cells displayed an increased level of DNA binding of Jun/Jun dimers to the probe, indicating that AP-1 was capable of binding to this promoter site. A luciferase reporter construct containing triplicate copies of the MDR1 promoter sequence was expressed at higher levels in transiently transfected MDR cells when compared to expression in WT cells. Co-transfection of WT cells with a c-jun expression vector and either of the AP-1 luciferase constructs demonstrated that c-jun could activate gene expression from both the consensus and the MDR1 AP-1 sites in a dose dependent manner. In addition, RT-PCR and western blot analysis showed that levels of MDR1 mRNA and Pgp were increased in c-jun transfected WT cells. Taken together, these data indicate that increased AP-1 activity may be an important mediator of MDR by regulating the expression of MDR1.
引用
收藏
页码:229 / 240
页数:12
相关论文
共 58 条
[1]   THE TRANSACTIVATING DOMAIN OF THE C-JUN PROTO-ONCOPROTEIN IS REQUIRED FOR COTRANSFORMATION OF RAT EMBRYO CELLS [J].
ALANI, R ;
BROWN, P ;
BINETRUY, B ;
DOSAKA, H ;
ROSENBERG, RK ;
ANGEL, P ;
KARIN, M ;
BIRRER, MJ .
MOLECULAR AND CELLULAR BIOLOGY, 1991, 11 (12) :6286-6295
[2]   THE ROLE OF JUN, FOS AND THE AP-1 COMPLEX IN CELL-PROLIFERATION AND TRANSFORMATION [J].
ANGEL, P ;
KARIN, M .
BIOCHIMICA ET BIOPHYSICA ACTA, 1991, 1072 (2-3) :129-157
[3]   PHORBOL ESTER INDUCIBLE GENES CONTAIN A COMMON CIS ELEMENT RECOGNIZED BY A TPA-MODULATED TRANS-ACTING FACTOR [J].
ANGEL, P ;
IMAGAWA, M ;
CHIU, R ;
STEIN, B ;
IMBRA, RJ ;
RAHMSDORF, HJ ;
JONAT, C ;
HERRLICH, P ;
KARIN, M .
CELL, 1987, 49 (06) :729-739
[4]   EXPRESSION OF A DRUG-RESISTANCE GENE IN HUMAN NEURO-BLASTOMA CELL-LINES - MODULATION BY RETINOIC ACID-INDUCED DIFFERENTIATION [J].
BATES, SE ;
MICKLEY, LA ;
CHEN, YN ;
RICHERT, N ;
RUDICK, J ;
BIEDLER, JL ;
FOJO, AT .
MOLECULAR AND CELLULAR BIOLOGY, 1989, 9 (10) :4337-4344
[5]  
BERGER SL, 1989, METHOD ENZYMOL, V180, P3
[6]  
BHUSHAN A, 1992, MOL PHARMACOL, V42, P69
[7]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[8]  
BROWN PH, 1993, ONCOGENE, V8, P877
[9]   TRANSFORMATION OF RAT-LIVER EPITHELIAL-CELLS WITH V-H-RAS OR V-RAF CAUSES EXPRESSION OF MDR-1, GLUTATHIONE-S-TRANSFERASE-P AND INCREASED RESISTANCE TO CYTO-TOXIC CHEMICALS [J].
BURT, RK ;
GARFIELD, S ;
JOHNSON, K ;
THORGEIRSSON, SS .
CARCINOGENESIS, 1988, 9 (12) :2329-2332
[10]   COINDUCTION OF MDR-1 MULTIDRUG-RESISTANCE AND CYTOCHROME-P-450 GENES IN RAT-LIVER BY XENOBIOTICS [J].
BURT, RK ;
THORGEIRSSON, SS .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1988, 80 (17) :1383-1386